Abstract
Targeting biologically relevant noncoding RNAs using small molecules is currently one of the major challenges of medicinal chemistry but holds a great potential for future therapeutic applications. In this context, oncogenic microRNAs represent a particularly promising target, and various examples of RNA binders have been reported as inhibitors of the biogenesis of these microRNAs. Here, we report the biochemical evaluation and molecular docking studies of five heterocycle-spermine conjugates revealing that a structure-based design of efficient and especially selective inhibitors can be performed based on the secondary and tertiary configuration of the targeted RNA.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
